Literature DB >> 22233693

Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009.

Peter Laszlo Lakatos1, Petra Anna Golovics, Gyula David, Tunde Pandur, Zsuzsanna Erdelyi, Agnes Horvath, Gabor Mester, Mihaly Balogh, Istvan Szipocs, Csaba Molnar, Erzsebet Komaromi, Gabor Veres, Barbara Dorottya Lovasz, Miklos Szathmari, Lajos S Kiss, Laszlo Lakatos.   

Abstract

OBJECTIVES: Medical therapy for Crohn's disease (CD) has changed significantly over the past 20 years with increasing use of immunosuppressives. In contrast, surgery rates are still high and there is little evidence that disease outcomes for CD have changed over the past decades. The objective of this study was to analyze the evolution of the surgical rates and medical therapy in the population-based Veszprem province database.
METHODS: Data of 506 incident CD patients were analyzed (age at diagnosis: 31.5 years, s.d. 13.8 years). Both hospital and outpatient records were collected and comprehensively reviewed. The study population was divided into three groups by the year of diagnosis (cohort A: 1977-1989, cohort B: 1990-1998 and cohort C: 1999-2008).
RESULTS: Overall, azathioprine (AZA), systemic steroid, and biological (only available after 1998) exposure was 45.8, 68.6, and 9.5%, respectively. The 1- and 5-year probability of AZA use were 3.2 and 6.2% in cohort A, 11.4 and 29.9% in cohort B, and 34.8 and 46.2% in cohort C. In a multivariate Cox-regression analysis, decade of diagnosis (P < 0.001, hazard ratio (HR)(cohorts B-C): 2.88-6.53), age at onset (P = 0.008, HR: 1.76), disease behavior at diagnosis (P < 0.001, HR(complicated): 1.76-2.07), and need for systemic steroids (P < 0.001, HR: 2.71) were significantly associated with the time to initiation of AZA therapy. Early AZA use was significantly associated with the time to intestinal surgery in CD patients; in a multivariate Cox analysis (HR: 0.43, 95% confidence interval (CI): 0.28-0.65) and after matching on propensity scores for AZA use (HR: 0.42, 95% CI: 0.26-0.67).
CONCLUSIONS: This population-based inception cohort has shown that the recent reduction in surgical rates was independently associated with increased and earlier AZA use.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22233693     DOI: 10.1038/ajg.2011.448

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  55 in total

Review 1.  Positioning therapy for Crohn's disease.

Authors:  Alexandra Gutierrez; Themistocles Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2014

2.  Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.

Authors:  Steven F G Jeuring; Vince B C Biemans; Tim R A van den Heuvel; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik
Journal:  Am J Gastroenterol       Date:  2018-01-09       Impact factor: 10.864

3.  Surgical recurrence after primary ileocolic resection for Crohn's disease.

Authors:  S Riss; I Schuster; P Papay; F Herbst; M Mittlböck; P Chitsabesan; A Stift
Journal:  Tech Coloproctol       Date:  2013-08-28       Impact factor: 3.781

4.  Natural history of Crohn's disease following total colectomy and end ileostomy.

Authors:  Joanna Lopez; Gauree G Konijeti; Deanna D Nguyen; Jenny Sauk; Vijay Yajnik; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 5.  Surgical recurrence in Crohn's disease: Are we getting better?

Authors:  Ivan Kristo; Anton Stift; Michael Bergmann; Stefan Riss
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

6.  Response to Magro et al.

Authors:  James Irwin; Graham Radford-Smith
Journal:  Am J Gastroenterol       Date:  2015-06       Impact factor: 10.864

7.  A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype.

Authors:  Sharif Yassin; Naomi Fliss Isakov; Yulia Ron; Nathaniel Aviv Cohen; Ayal Hirsch; Nitsan Maharshak
Journal:  Int J Colorectal Dis       Date:  2021-01-06       Impact factor: 2.571

8.  Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort.

Authors:  Steven F G Jeuring; Tim R A van den Heuvel; Limmie Y L Liu; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik
Journal:  Am J Gastroenterol       Date:  2016-12-06       Impact factor: 10.864

9.  The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease.

Authors:  Andres J Yarur; Maria T Abreu; Mark S Salem; Amar R Deshpande; Daniel A Sussman
Journal:  Dig Dis Sci       Date:  2013-03-13       Impact factor: 3.199

10.  Is early limited surgery associated with a more benign disease course in Crohn's disease?

Authors:  Petra Anna Golovics; Laszlo Lakatos; Attila Nagy; Tunde Pandur; Istvan Szita; Mihaly Balogh; Csaba Molnar; Erzsebet Komaromi; Barbara Dorottya Lovasz; Michael Mandel; Gabor Veres; Lajos S Kiss; Zsuzsanna Vegh; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.